Biohaven Q3 net loss narrows to $129.3 million from $173.4 million
Biohaven reported a third-quarter 2026 net loss of $129.3 million, or $0.86 per share, compared with $173.4 million, or $1.64 per share, a year earlier, as research and development spending fell to $101.9 million from $141.2 million. The company also announced an Ono Pharmaceutical license for its MoDE IgG degrader portfolio, with up to $100 million in near-term payments, and said its SK Biopharmaceuticals license for opakalim will bring $400 million in cash consideration once it closes. Shareholders' equity was a deficit of $98.2 million at September 30, 2026.
Key points
- Net loss of $129.3 million ($0.86 per share) for Q3 2026, versus $173.4 million ($1.64 per share) in Q3 2025
- R&D expenses were $101.9 million, down from $141.2 million; G&A expenses were $24.6 million, down from $28.2 million
- Ono license: up to $100 million in near-term payments, including $80 million received to date
- SK Biopharmaceuticals deal: $400 million cash consideration, with $350 million payable at closing; HSR waiting period expired October 28, 2026
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.